Flexion Reports Year-End 2015 Financial Results
Mar 10, 2016 21:01 pm UTC| Business
Pivotal registration trials completed in patients with osteoarthritis (OA) of the knee for Zilretta™, Flexion’s lead drug candidate (also known as FX006)Zilretta received Fast-Track designation by U.S. Food Drug...
Mar 10, 2016 21:00 pm UTC| Business
DENVER, March 10, 2016 -- Bonanza Creek Energy, Inc. (NYSE:BCEI) announces it has elected to draw down $209 million on its credit facility, and currently has an aggregate of $300 million of borrowings, including a $12...
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2015 Results
Mar 10, 2016 21:00 pm UTC| Business
NASHVILLE, Tenn., March 10, 2016 -- Surgery Partners, Inc.(NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading provider of surgical services, today announced results for the fourth quarter and full year...
Kratos Reports Fourth Quarter and Fiscal 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
Fourth Quarter Revenues of $177.5M Increase 9.8% Over Third Quarter Full Year Revenues of $657.1M Fourth Quarter Adjusted EBITDA of $13.4 Million SAN DIEGO, March 10, 2016 -- Kratos Defense Security Solutions,...
STRATA Skin Sciences Reports Fourth Quarter 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
Proforma XTRAC Recurring Revenue Growth of 16.1% in CY 2015 Achieved Positive Non-GAAP Adjusted EBIDTA for Second Consecutive Quarter HORSHAM, Pa., March 10, 2016 -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN)...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
Mar 10, 2016 21:00 pm UTC| Business
EMERYVILLE, Calif., March 10, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and...
STRATA Skin Sciences, Inc. Announces FDA Approval of PMA Supplemental for MelaFind®
Mar 10, 2016 21:00 pm UTC| Business
Study including Classifier Score Data shows increased Sensitivity and Specificity FDA Post-Approval Study Termination provides cost savings Greater flexibility to explore strategic value of MelaFind System in Clinical...